Novartis misses quarterly sales, profit estimates as Entresto generics hit growth - Reuters

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPaFRwVUxuUFZGS1FpeEZfQlRRZVQtdUFEZ0tKQmNuTzFlSnYwWnRCN0dzbmZFb25ta3JfdFFCTmlRNHVFM082R2VaWFhFYjVSLXhQaDZwdERHTFBmeU82a1VQNzdONHZ6LXlJNnEzeUJHMkxOYllfVEp0dnp4M2w5M2x3emFqTFZGZnNpamRGSjRkazd6NnNFMFBIeUZNb1dCN29PTVZUUU5jWHdScWVJSHBlX1E?oc=5" target="_blank">Novartis misses quarterly sales, profit estimates as Entresto generics hit growth</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Novartis reported a core earnings per share of $1.99 in Q1 2026, below Bloomberg estimates of $2.10, with net sales declining 1% year-on-year to $13.11 billion due to increasing competition from generics. The company maintained its annual guidance of low single-digit growth in net sales and a low single-digit decline in core operating income.

Novartis reported first-quarter core operating profit below market expectations, as generic competition for its top-selling heart drug Entresto weighed on sales. The company's operating income declined 12% to $4.9 billion, below analyst expectations of about $5.1 billion.

Novartis reported first-quarter core operating profit below market expectations, as generic competition for its top-selling heart drug Entresto weighed on sales. The company's operating income declined 12% to $4.9 billion, below analyst expectations of about $5.1 billion.

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.

Novartis reported Q1 2026 core operating income of $4.9 billion and net sales of $13.11 billion, both below analyst forecasts, as generic competition for Entresto impacted results. The company reaffirms its full-year outlook, expecting sales and profit to rebound in the second half of the year.